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Abstract
Introduction The aim of our study was to investigate the
association between arthritic disease activity and antibodies to
mutated citrullinated vimentin (anti-MCV), because such a
relation has been suggested.
Methods Anti-MCV levels were measured in 162 patients with
early arthritis (123 with rheumatoid arthritis and 39 with
undifferentiated arthritis) at baseline and at 1 and 2 years of
follow up. Disease activity was measured using the disease
activity score (Disease Activity Score based on 28 joints
[DAS28]) and serum C-reactive protein. General estimation
equation analysis was used to assess the relation between anti-
MCV levels and DAS28 over time.
Results Both, anti-MCV levels and DAS28 exhibited a
significant decrease during the first and second year. However,
the association between anti-MCV levels and DAS28, adjusted
for dependency on sequential measurements within one
individual, was very low (β = 0.00075). In a population of
patients with rheumatoid arthritis or undifferentiated arthritis,
anti-MCV had a specificity of 92.3% and a sensitivity of 59.3%
when using the recommended cut-off of 20 U/ml. Specificity
and sensitivity of antibodies against second-generation cyclic
citrullinated peptide, using the recommended cut-off value of 25
U/ml, were 92.1% and 55.3%, respectively. Anti-MCV-positive
early arthritis patients had significantly higher Sharp-van der
Heijde score, erythrocyte sedimentation rate and C-reactive
protein levels than did anti-MCV-negative patients at all time
points (P < 0.005), but DAS28 was higher in anti-MCV-positive
patients at 2 years of follow up only (P < 0.05).
Conclusion Because the correlation between anti-MCV levels
and parameters of disease activity was very low, we conclude
that it is not useful to monitor disease activity with anti-MCV
levels.
Introduction
At present, two types of serological markers are used in the
early diagnosis of rheumatoid arthritis (RA): antibodies to the
Fc part of human IgG (rheumatoid factor) and antibodies to cit-
rullinated protein/peptide antigens (ACPAs). Rheumatoid fac-
tor is not specific to RA, because it is present in patients
suffering from other autoimmune and/or infectious diseases
and are found in apparently healthy elderly patients [1].
ACPAs have a high specificity for RA. Since the first descrip-
tion of RA-specific antibodies to citrullinated peptides, several
citrullinated proteins have been proposed as physiological tar-
gets for ACPA specificity, such as fibrin [2], Epstein-Bar virus
nuclear antigen [3], α-enolase [4] and vimentin [5].
Antibodies against second-generation cyclic citrullinated pep-
tide (anti-CCP2) are frequently used by clinicians to assess
RA. Anti-CCP2 level has a good diagnostic and prognostic
value [6], but in one study [7] no relation between anti-CCP2Page 1 of 6
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based on 28 joints [DAS28]) was identified. Citrullinated
vimentin has been shown to be the target for the previously
described RA-specific Sa antibodies [5]. In a cohort of
patients with early arthritis, the presence of Sa antibodies cor-
related with a more dramatic disease presentation [8].
Recently, an ELISA for the detection of antibodies against
human mutated citrullinated vimentin (MCV) was developed
[9]. Anti-MCV level had high sensitivity in patients with estab-
lished RA [9,10]. Also, anti-MCV levels correlated with DAS28
score in a small population of 21 patients with RA over a
period of 3 years [9]. The present study focuses on the asso-
ciation between anti-MCV levels and DAS28 in patients with
early arthritis over 2 years of follow up. In addition, sensitivity
and specificity of the anti-MCV test were determined in a
group of patients with early arthritis.
Materials and methods
Patients
The study population included 162 patients (age ≥ 18 years)
with peripheral arthritis of two or more joints and with symptom
duration of 3 years or less, who had been newly referred to the
early arthritis clinic of the Jan van Breemen Institute (a large
rheumatology clinic in Amsterdam, The Netherlands) between
1995 and 1998. Patients who were previously treated with a
disease-modifying antirheumatic drug and patients with
spondylarthropathy, reactive arthritis, crystal-induced arthrop-
athy, systemic lupus erythematosus, Sjögren's syndrome, or
osteoarthritis were excluded. Baseline was defined as the first
presentation to the rheumatologist. Sera were available from
baseline and at 1 and 2 years of follow up. After 1 year of fol-
low up patients were diagnosed as having RA or undifferenti-
ated arthritis (UA) after chart review by an experienced
rheumatologist (BD), who was blinded to the results of anti-
body testing. The local ethics committee (Slotervaart Hospital,
Jan van Breemen Institute and BovenIJ Hospital, Amsterdam,
The Netherlands) approved the study protocol. All patients
gave written informed consent to be included in the study.
Disease parameters
At baseline the following data were collected: demographic
characteristics; disease duration; disease activity, as meas-
ured using DAS28 [11]; patient pain, using visual-analogue
scale (VAS); and functional status, causing Health Assess-
ment Questionnaire [12]. Laboratory assessments at baseline
included erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP), and anti-CCP2. Radiographs of hands and feet
were obtained at baseline, and at 1 and 2 years. The number
of erosions and the joint space narrowing were scored accord-
ing to the Sharp/van der Heijde method [13] by an experi-
enced rheumatologist (DvS), who was unaware of the other
data.
Antibody measurements
Anti-CCP2 levels were measured using the second-genera-
tion Immunoscan RA ELISA kit (Euro-diagnostica, Arnhem,
The Netherlands) with a cut-off value of 25 U/ml, as proposed
by the manufacturer. ELISA kits for detection of anti-MCV
were generously provided by ORGENTEC Diagnostica
GmbH (Mainz, Germany) and were used in accordance with
the manufacturer's instructions [9] with the recommended cut-
off value of 20 U/ml. Anti-CCP2 levels were determined at
baseline and anti-MCV levels were measured at baseline and
at 1 and 2 years of follow up.
Analysis
The baseline characteristics of the RA patients and UA
patients were compared using Student's t-test, the Mann-
Whitney U-test and the χ2 test, as appropriate. Correlation
between anti-MCV levels and DAS28, anti-CCP2 levels, or
radiographic progression was determined using Spearman
correlation. General estimation equation (GEE) analysis was
used to determine the relation between anti-MCV levels and
DAS28 over time. This regression technique was used
because it adjusts for dependency of several measurements
within one individual and it is capable of dealing with missing
data [14]. Sensitivity, specificity and positive predictive value
of anti-MCV were calculated in the 162 patients with early
arthritis.
Sensitivity expresses the percentage of RA patients who was
positive for the test, whereas specificity is calculated from the
percentage of test-negative UA patients.
Radiographic progression was defined as an increase of
Sharp-van der Heijde score (SHS) of at least 5 after 2 years of
follow up [15]; the remaining patients were classified as being
nonprogressive. GEE analysis was performed using STATA
7.0 (Stata Corp., College Station, TX, USA); other statistical
analyses were performed using SPSS 15.0 software (SPSS
Institute Inc., Cary, NC, USA).
Results
Relationship of serum anti-MCV levels with the course of 
disease activity
The median anti-MCV level at baseline was 14 U/ml (interquar-
tile range 6 to 289 U/ml) and at 1 year and 2 years of follow
up the levels were 9 U/ml (5 to 197 U/ml) and 10 U/ml (4 to
153 U/ml), respectively. Anti-MCV values were missing in two
UA patients at 1 year of follow up and in one RA patient at 2
years of follow up. Anti-MCV levels as well as DAS28
decreased significantly during the first year, but changes in
DAS28 did not correlate with changes in anti-MCV levels (r =
0.06; P = 0.44). The correlations between anti-MCV level and
CRP at all time points combined (r = 0.23; P < 0.01) and
between anti-MCV level and DAS28 at all time points com-
bined (r = 0.17; P < 0.05) were rather low. The correlations
between anti-MCV level and two separate components ofPage 2 of 6
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joints]) were also rather low (r = 0.27 and r = 0.11, respec-
tively; P < 0.05). No correlation was identified between tender
joint count (of a total of 28 joints) and general health deter-
mined using a VAS (r = 0.2 and r = 0.03, respectively; P >
0.05). Correlations between anti-MCV levels at baseline and
SHS at 2 years of follow up and between anti-CCP2 levels
and SHS at 2 years of follow up were similar (r = 0.42 and r =
0.41, respectively; P < 0.01). No correlation was found
between anti-CCP2 levels and DAS28 at baseline (r = 0.12;
P = 0.14).
GEE analysis revealed a significant association between
DAS28 and anti-MCV during 2 years of follow up, although the
association was very low. The β coefficient (slope of the
regression) of anti-MCV was small (β = 0.00075; P <
0.0001). Thus, if anti-MCV levels increase by 1 unit, DAS28
score will rise 0.00075 points. The β can be multiplied by the
increase in anti-MCV levels to calculate the increase in
DAS28. To study the relationship between anti-MCV levels
and DAS28 in more detail, patients were categorized as being
positive or negative for anti-MCV at baseline. Of the 162
patients in our cohort, 76 (73 patients with RA and three
patients with UA) were positive for anti-MCV at baseline. The
mean age, percentage of females and mean disease duration
were not different between the two groups. A few patients
changed anti-MCV status in time (10/162 [6.2%]). Two ini-
tially anti-MCV-negative RA patients became positive,
although their anti-MCV levels were just above the cut-off
point. Eight initially anti-MCV-positive patients became nega-
tive (one UA patient and seven RA patients). Anti-MCV levels
from these patients were low at baseline (20 to 119 U/ml).
In the anti-MCV-positive and anti-MCV-negative patient group,
mean DAS28 score decreased mainly during the first year,
from 5.0 and 4.8 to 3.5 and 3.3, respectively. During the sec-
ond year, mean DAS28 score of anti-MCV-positive patients
remained stable, whereas mean DAS28 score of anti-MCV-
negative patients decreased further (mean DAS28 scores 3.5
and 3.1, respectively). At baseline, DAS28 tended to be
higher in anti-MCV-positive patients (P = 0.08). The difference
became significant after 2 years of follow up (P < 0.05; Figure
1). Anti-MCV-positive patients had higher median ESR and
CRP levels (P < 0.05 and P < 0.005, respectively) than did
anti-MCV-negative patients at all time points (Figure 1). In
addition to differences in parameters of inflammation, signifi-
cant differences in radiographic damage were also found (Fig-
ure 1). Anti-MCV-positive patients had more radiographic
damage at all time points (P < 0.005). There was no correla-
tion between symptom duration and degree of radiographic
damage at baseline (r = 0.06, P = 0.47). The mean duration of
symptoms was not different between anti-MCV-positive and
anti-MCV-negative patients (0.59 and 0.60 years,
respectively).
In addition, a comparison between anti-MCV-positive and anti-
MCV-negative RA patients was conducted, because the main
group of UA patients appeared to be anti-MCV negative.
Except for the median SHS at baseline (P = 0.002), there
were no differences between the groups of anti-MCV-positive
and anti-MCV-negative RA patients at baseline. DAS28 score
did not differ significantly between the two groups over 2 years
of follow up. Anti-MCV-positive RA patients had higher median
CRP levels at 1 and 2 years of follow up and higher median
ESR levels at 2 years of follow up (all P < 0.05) than did anti-
MCV-negative RA patients. In addition, anti-MCV-positive RA
patients had more radiographic damage at all time points (P <
0.005).
Value of the anti-MCV test in early arthritis
At baseline, RA patients had a higher median ESR, CRP and
SHS, and a higher mean DAS28 score and Health Assess-
ment Questionnaire score than did UA patients (Table 1). Sen-
sitivity, specificity and positive predictive value of anti-MCV for
the diagnosis of RA at 1 year of follow up are shown in Table
2. Positivity for anti-MCV and anti-CCP was largely overlap-
ping, although six of the 90 anti-CCP2-negative patients were
positive for anti-MCV at baseline. Five of them had been diag-
nosed with RA and one with UA by an experienced rheumatol-
ogist who was blinded to the ACPA findings after the first year.
One patient, diagnosed with UA, was positive for anti-CCP but
negative for anti-MCV. Levels of anti-MCV and anti-CCP2 at
baseline were highly correlated (r = 0.85; P < 0.01). The per-
centage of patients who used methotrexate during 2 years fol-
low up was significantly higher in the anti-MCV-positive group
than in the anti-MCV-negative group (43% versus 28%; P =
0.039). In addition, the percentage of patients who used sul-
fasalazine was significantly higher in the anti-MCV-positive
group than in the anti-MCV-negative group (75% versus 60%;
P = 0.049).
Discussion
The main focus of our study was to investigate the relation
between anti-MCV levels and disease activity. Previously,
Bang and coworkers [9] analyzed consecutive samples of 21
patients with established RA over a 2-year period of follow up
and identified a correlation between anti-MCV levels and
DAS28 score (Pearson correlation coefficient 0.404),
whereas no correlation was found between anti-CCP2 levels
and DAS28 score. Although in our cohort of 76 anti-MCV-pos-
itive patients with early arthritis the median anti-MCV level and
DAS28 score both decreased over time, GEE analysis
revealed a rather small association between anti-MCV levels
and DAS28 score over 2 years of follow up. This implies that
a large decline in anti-MCV level is needed to yield a substan-
tial decrease in DAS28. A minimal reduction of 0.6 points in
DAS28 is necessary for a moderate response, according to
the European League Against Rheumatism response criteria
[16]. Anti-MCV levels would have to decrease by 800 U/ml to
account for such a reduction in DAS28 score. In our cohort,Page 3 of 6
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U/ml during the first year and one patient in the second year.
In addition, we did not identify a direct relationship between
changes in anti-MCV levels and changes in disease activity,
expressed as DAS28 score. The correlation between anti-
MCV levels and CRP, DAS28, or its separate components
ESR and swollen joint count was rather low, and was absent
between anti-MCV levels and tender joint count and VAS gen-
eral health. Previous studies of anti-CCP2 levels and disease
activity yielded inconsistent results. One study [17] found cor-
responding changes between these two parameters, whereas
others found no correlation [7,18]. In our cohort we did not
find a substantial association between anti-MCV levels and
disease activity. Together with the high correlation between
anti-MCV and anti-CCP2 levels, our data suggest that testing
ACPA on citrullinated protein substrates is comparable to
testing on artificial citrullinated peptides, and that anti-MCV
levels cannot be used to monitor disease activity directly.
When comparing patients with established RA versus control
patients, reported sensitivities and specificities of anti-MCV
ranged from 69.5% to 74.5% versus 90.3% to 93.1%,
respectively [10,19,20]. These studies also used the recom-
mended cut-off value of 20 U/ml. In our early arthritis popula-
tion comprising only RA and UA patients, the sensitivity of
59.3% was lower than previously reported sensitivities. The
specificity of 92.3% was rather low but comparable to those
of previous studies. Interestingly, the specificity of anti-CCP2
using a cut-off value of 25 U/ml was also low (92.1%) and
comparable to that of anti-MCV in our cohort. The low specif-
icities for both ACPA tests might be explained by the inclusion
of RA and UA patients only. It cannot be excluded that UA
patients will convert to RA later in time. Thus far (10 years from
inclusion), five of the UA patients have developed RA. One out
of three anti-MCV-positive patients and four out of 36 anti-
MCV-negative patients developed RA. Taking that into
account, the sensitivity of anti-MCV will slightly decrease and
specificity will slightly increase.
Figure 1
Arthritic disease activity: anti-MCV positive versus anti-MCV negative patients. Statistical comparisons were performed between anti-mutated citrull-
inated vimentin (anti-MCV)-positive and anti-MCV-negative patients at the indicated time points. Dotted lines represent anti-MCV-positive patients, 
and straight lines represents anti-MCV-negative patients. *P < 0.05; **P < 0.005. CRP, C-reactive protein; DAS28, Disease Activity Score based on 
28 joints; ESR, erythrocyte sedimentation rate.Page 4 of 6
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had significantly greater radiologic damage than did anti-MCV-
negative RA patients. This could not be accounted for by
longer symptom duration in anti-MCV-positive patients. Clini-
cians were unaware of anti-CCP2 or anti-MCV status because
these were determined retrospectively and patients were
treated according to DAS28 score. Nevertheless, despite this
treatment the difference in radiological damage became even
more evident after 2 years of follow up. Differences in disease
activity have been reported for anti-CCP2-positive patients
with early arthritis after the first [7] and second year [21] of fol-
low up. In our cohort, at baseline anti-CCP2-positive patients
were similar to anti-MCV-positive patients, and exhibited sig-
nificantly higher levels of CRP and ESR and a higher SHS.
Conclusion
In summary, anti-MCV-positive patients exhibited higher levels
of inflammation and more radiographic damage at baseline
than did anti-MCV-negative patients. Both DAS28 and anti-
MCV levels decreased significantly during 2 years of follow up.
However, because the correlation between anti-MCV levels
and parameters of disease activity was very low, it is not useful
to measure anti-MCV levels to monitor disease activity.
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Table 1
Baseline characteristics of the early arthritis population: RA and UA patients
Baseline characteristics RA (n = 123) UA (n = 39) P value
Age (years)a 56.4 ± 15.0 53.8 ± 14.0 NS
Female (%)b 86 (69.9) 26 (66.7) NS
Disease duration (years)c 0.4 (0.3 to 0.6) 0.4 (0.3 to 0.8) NS
ESR (mm/hour)a 36.7 ± 24.4 23.7 ± 21.0 <0.005
CRP (mg/dl)c 19.5 (6.5 to 45.5) 6 (2 to 15) <0.005
Anti-CCP2 positive (%) 68 (55.3) 3 (7.9) <0.005
Anti-MCV positive (%) 73 (59.3) 3 (7.7) <0.005
DAS28 scorea 5.1 ± 1.2 4.3 ± 1.2 <0.01
Sharp-van der Heijde scorec 2 (0 to 6) 0 (0 to 1) <0.01
HAQ scorea 1.1 ± 0.7 0.8 ± 0.6 p < 0.05
Data are expressed as mean ± standard deviation or as median (Interquartile range). aTested using Student's t-test. bTested using the χ2 test. 
cTested using the Mann Whitney U-test. CCP2, second-generation cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity 
Score of 28 joints; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MCV, mutated citrullinated vimentin; NS, not 
significant; RA, rheumatoid arthritis; UA, undifferentiated arthritis.
Table 2
Sensitivity, specificity and positive predictive value of anti-MCV and anti-CCP for clinical diagnosis of RA in early arthritis patients
Antibody Sensitivity (%; 95% CI) Specificity (%; 95% CI) PPV (%)
Anti-CCP2 level ≥ 25 U/ml 55.3 (46.1 to 64.2) 92.1 (77.5 to 97.9) 95.8
Anti-MCV level ≥ 20 U/ml 59.3 (50.1 to 67.9) 92.3 (78.0 to 97.9) 96.1
Shown are the sensitivity, specificity and positive predictive value (PPV) of anti-mutated citrullinated vimentin (anti-MCV) and anti-second-
generation cyclic citrullinated peptide (anti-CCP2) for the clinical diagnosis of rheumatoid arthritis (RA) in early arthritis, using cut off values 
recommended by the manufacturers of the tests. A total of 162 patient with early arthritis were included in the analysis. CI, confidence interval.Page 5 of 6
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 10 No 1    Ursum et al.ARvdH performed laboratory work. RJvdS provided patient
material. BD was involved in classifying the clinical diagnosis.
DH participated in study design, interpreted the data and
drafted the manuscript.
Acknowledgements
We would like to thank E de Wit-Taen and A Abrahams for collecting 
patient data.
References
1. van Schaardenburg D, Lagaay AM, Otten HG, Breedveld FC: The
relation between class-specific serum rheumatoid factors and
age in the general population.  Br J Rheumatol 1993,
32:546-549.
2. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L,
Vincent C, Senshu T, Serre G: The major synovial targets of the
rheumatoid arthritis-specific antifilaggrin autoantibodies are
deiminated forms of the alpha- and beta-chains of fibrin.  J
Immunol 2001, 166:4177-4184.
3. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P: Deimi-
nated Epstein-Barr virus nuclear antigen 1 is a target of anti-
citrullinated protein antibodies in rheumatoid arthritis.  Arthritis
Rheum 2006, 54:733-741.
4. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P,
Moyes D, Taylor PC, Venables PJ: Identification of citrullinated
alpha-enolase as a candidate autoantigen in rheumatoid
arthritis.  Arthritis Res Ther 2005, 7:R1421-R1429.
5. Vossenaar ER, Despres N, Lapointe E, van der HA, Lora M, Senshu
T, van Venrooij WJ, Menard HA: Rheumatoid arthritis specific
anti-Sa antibodies target citrullinated vimentin.  Arthritis Res
Ther 2004, 6:R142-R150.
6. Riedemann JP, Munoz S, Kavanaugh A: The use of second gen-
eration anti-CCP antibody (anti-CCP2) testing in rheumatoid
arthritis: a systematic review.  Clin Exp Rheumatol 2005,
23:S69-S76.
7. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog
L, van Vollenhoven RF: Longitudinal analysis of citrullinated pro-
tein/peptide antibodies (anti-CP) during 5 year follow up in
early rheumatoid arthritis: anti-CP status predicts worse dis-
ease activity and greater radiological progression.  Ann Rheum
Dis 2005, 64:1744-1749.
8. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C,
Smolen JS, Steiner G, Rosen A, Zhang C, Ménard HA, Zhou ZJ,
Palosuo T, Van Venrooij WJ, Wilder RL, Klippel JH, Schumacher
HR Jr, El-Gabalawy HS: Rheumatoid arthritis associated
autoantibodies in patients with synovitis of recent onset.
Arthritis Res 2000, 2:236-243.
9. Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen
G, Berg W, Feist E, Burmester GR: Mutation and citrullination
modifies vimentin to a novel autoantigen for rheumatoid
arthritis.  Arthritis Rheum 2007, 56:2503-2511.
10. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M:
Diagnostic value of antibodies against a modified citrullinated
vimentin in rheumatoid arthritis.  Arthritis Res Ther 2006,
8:R119.
11. Prevoo ML, 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte
LB, van Riel PL: Modified disease activity scores that include
twenty-eight-joint counts. Development and validation in a
prospective longitudinal study of patients with rheumatoid
arthritis.  Arthritis Rheum 1995, 38:44-48.
12. Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of
patient outcome in arthritis.  Arthritis Rheum 1980, 23:137-145.
13. van der Heijde DM, van Leeuwen MA, van Riel PLCM, Koster AM,
van 't Hof MA, van Rijswijk MH, van de Putte LBA: Biannual radi-
ographic assessments of hands and feet in a three-year pro-
spective followup of patients with early rheumatoid arthritis.
Arthritis Rheum 1992, 35:26-32.
14. Twisk JW: Longitudinal data analysis. A comparison between
generalized estimating equations and random coefficient
analysis.  Eur J Epidemiol 2004, 19:769-776.
15. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P,
Paulus H, Houben H, Griffiths B, Edmonds J, Bresnihan B, Boonen
A, van der Linden S: Determination of the minimal clinically
important difference in rheumatoid arthritis joint damage of
the Sharp/van der Heijde and Larsen/Scott scoring methods
by clinical experts and comparison with the smallest detecta-
ble difference.  Arthritis Rheum 2002, 46:913-920.
16. van Gestel AM, Prevoo ML, 't Hof MA, van Rijswijk MH, van de
Putte LB, van Riel PL: Development and validation of the Euro-
pean League Against Rheumatism response criteria for rheu-
matoid arthritis. Comparison with the preliminary American
College of Rheumatology and the World Health Organization/
International League Against Rheumatism Criteria.  Arthritis
Rheum 1996, 39:34-40.
17. Aotsuka S, Okawa-Takatsuji M, Nagatani K, Nagashio C, Kano T,
Nakajima K, Ito K, Mimori A: A retrospective study of the fluctu-
ation in serum levels of anti-cyclic citrullinated peptide anti-
body in patients with rheumatoid arthritis.  Clin Exp Rheumatol
2005, 23:475-481.
18. Greiner A, Plischke H, Kellner H, Gruber R: Association of anti-
cyclic citrullinated peptide antibodies, anti-citrullin antibodies,
and IgM and IgA rheumatoid factors with serological parame-
ters of disease activity in rheumatoid arthritis.  Ann N Y Acad
Sci 2005, 1050:295-303.
19. Bizzaro N, Tonutti E, Tozzoli R, Villalta D: Analytical and diagnos-
tic characteristics of 11 2nd- and 3rd-generation immunoenzy-
matic methods for the detection of antibodies to citrullinated
proteins.  Clin Chem 2007, 53:1527-1533.
20. Coenen D, Verschueren P, Westhovens R, Bossuyt X: Technical
and diagnostic performance of 6 assays for the measurement
of citrullinated protein/peptide antibodies in the diagnosis of
rheumatoid arthritis.  Clin Chem 2007, 53:498-504.
21. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G,
Rantapaa-Dahlqvist S: Radiological outcome in rheumatoid
arthritis is predicted by presence of antibodies against cyclic
citrullinated peptide before and at disease onset, and by IgA-
RF at disease onset.  Ann Rheum Dis 2006, 65:453-458.Page 6 of 6
(page number not for citation purposes)
